SCARLETRED is honored to be featured in the nationwide journal Rare Diseases. The article highlights how Scarletred® Vision, our certified smartphone-based Software as a Medical Device, supports 3D Skin assessment using our validated AI Agent ARORA®AI.

The AI MedTech specialist is setting the benchmark and new standards in digital dermatology through its dynamic Scarletred® Skin Patch based image calibration method, bundled with its Mobile App and Web Platform.  

As a Modular SaaS Platform, Scarletred®Vision  enables ICH-GCP- and data protection-compliant remote skin monitoring – improving global care for rare diseases such as Epidermolysis Bullosa (EB).

Why EB needs secure mobile digital skin assessment

Objective documentation and assessment of EB lesions are crucial for accurately tracking disease progression and making well-informed treatment decisions. However, for many patients – especially children – frequent hospital visits are time-consuming, painful, and burdensome.  

The medical device certified system provides a secure, mobile, and scalable skin imaging solution that runs directly on smartphones – making it easily accessible and barrier-free.

EB affects one in 50,000 births

This innovation is particularly important for Epidermolysis Bullosa (EB), a rare genetic disorder affecting approximately one in 50,000 births. Often referred to as “butterfly children”, those affected live with extremely fragile skin, chronic wounds, infection risks and often severe complications.  

Despite progress driven by research, care remains complex and inconsistent, often lacking reliable telemedical tools. The 2D and 3D Imaging Technology of Scarletred® Vision helps in EB assessment and monitoring:

• Scarletred® Vision delivers high-quality image data, automatically segments lesions, detects wounds, classifies tissue types and tracks blister formation over time.
• A single calibrated smartphone image turns into a reliable clinical dataset – subjective descriptions or bad imaging data are a thing of the past.  
• With its mobile 2D and 3D Imaging Technology, SCARLETRED detects blisters in their early stages.  
• The software not only identifies their location, but also assesses their stage (fluid-filled, ruptured, or crusted) and precisely measures their area, depth, and volume.

Beyond detecting and counting blisters, Scarletred® Vision quantifies and monitors them over time. This enables earlier treatment, improved monitoring of wound progression and healing, and ultimately helps reduce severity and size of resulting wounds.

“We support patients at home - with their families”

Beyond supporting the development of new EB therapies, the company’s mission primarily follows one core goal, as CEO Harald Schnidar explains: 

“In rare diseases such as EB, where conventional tools reach their limits, certified medical, trustful AI is not a distant vision of the future. Together with our partners and patients, we support and bring medical and trustful AI innovation to patients where they spend most of their lives – not in hospitals, but at home - with their families.” 

Further explore our research on Dermatology Innovation for Epidermolysis Bullosa (EB) here.